Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug developer Neurocrine Biosciences
So what: The preliminary results are in from Neurocrine's Phase IIa study on its treatment for Tardive Dyskinesia and they look good. Tardive Dyskinesia is a disorder characterized by involuntary movement and often stems from long-term use of certain schizophrenia treatments. Using the Abnormal Involuntary Movement Scale, the study showed an overall 41.3% decrease in the involuntary movements among the treated group. The company is now initiating an Investigational New Drug application with the Food and Drug Administration.
Now what: For investors in drug developers, these positive milestones are always good news. Neurocrine scored some upfront cash from its partnership with Abbott
Want to keep up to date on these stocks? Add Neurocrine Biosciences and Abbott Labs to your watchlist.